IGC

IGC Pharma, Inc. · AMEX

Sector Health Technology
Industry Biotechnology
Website igcpharma.com
Employees(FY) 61
ISIN US45408X3089

Performance

-12.54%

-14.65%

-21.85%

-40.48%

+18.99%

YTD

+10.73%

Profile

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Advanced Technical Analysis

Technical Analysis of IGC 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IGC

Stock Rank

Recent News & Updates

2024-11-13 19:30
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline(Accesswire)
2024-11-05 19:30
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies(Accesswire)
2024-10-16 20:30
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1(Accesswire)
2024-10-02 21:00
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge(Yahoo Finance)
2024-09-17 20:00
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment(Yahoo Finance)
2024-09-03 20:00
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease(Yahoo Finance)
2024-08-26 07:00
IGC Announces Results of its 2024 Annual Stockholders Meeting(Yahoo Finance)
2024-08-21 21:00
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease(Yahoo Finance)
2024-08-19 20:00
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist(Yahoo Finance)
2024-08-08 09:30
IGC Pharma Reports First Quarter Fiscal 2025 Results(Yahoo Finance)
2024-07-17 21:00
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target(Yahoo Finance)
2024-07-08 21:10
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile(Yahoo Finance)
2024-06-24 21:00
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease(Yahoo Finance)
2024-06-24 07:30
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024(Yahoo Finance)
2024-06-17 21:00
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets(Yahoo Finance)
2024-06-09 21:00
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol(Yahoo Finance)
2024-05-27 21:00
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1(Yahoo Finance)
2024-05-21 02:00
IGC Pharma to Attend BIO International Convention 2024(Yahoo Finance)
2024-05-08 20:45
6.7 Million Americans Live With Alzheimer's - IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings(Newsdirect)
2024-04-15 19:00
IGC-AD1s Interim Phase 2 Data Show a Reduction in Alzheimers Agitation at Week Two(Yahoo Finance)
2024-04-08 21:00
IGC Pharma Adds Advisor in Artificial Intelligence(Yahoo Finance)
2024-04-02 21:00
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research(Newsdirect)
2024-03-26 03:00
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock(Yahoo Finance)
2024-03-19 23:00
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimers Agitation(Yahoo Finance)
2024-03-19 19:00
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024(Yahoo Finance)
2024-03-19 04:00
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1(Newsdirect)
2024-03-12 03:00
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimers Pipeline(Yahoo Finance)
2024-02-28 00:00
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model(Yahoo Finance)
2024-02-22 23:01
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target(Yahoo Finance)
2024-02-16 06:05
IGC Pharma Reports Third Quarter Fiscal 2024 Results(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.